摘要
近年来肺癌的靶向治疗取得了很大的进展,多种分子驱动基因陆续被发现,如MET、Her-2、RET、KRAS、BRAF、NTRK、MEK、TROP2过表达、FGFR通路异常等。针对新靶点设计的药物层出不穷。但是患者在接受靶向治疗一段时间后往往会不可避免地出现靶向药耐药的问题。全文对肺癌靶向药物治疗中的新靶点和耐药特点作一综述。
Targeted therapy of lung cancer has made great progress in the past decade. Based on the discovery of novel targets such as MET,Her-2,RET,KRAS,BRAF,NTRK,MEK,TROP2 over-expression and abnormal FGFR pathway,new targeting drugs are emerging for lung cancer.But drug resistance always occurs soon after the new drug developed. The mechanisms of drug resistance includes primary resistance and secondary resistance,and re-biopsy plays an important role in discovering the mechanisms. This article summarizes the new targets in lung cancer and characteristics of drug resistance in targeted agents for lung cancer.
作者
张田利
展平
吕镗烽
宋勇
ZHANG Tian-li;ZHAN Ping;LV Tang-feng;SONG Yong(Medical School of Soulheast University,nanjing 210009,China;Jinling Hospital Affiliated to Nanjing University School of Medicine Nanjing 210002,China)
出处
《肿瘤学杂志》
CAS
2020年第9期826-832,共7页
Journal of Chinese Oncology
基金
国家自然科学基金(81772500
81602015)。
关键词
肺癌
靶向治疗
靶点
耐药
lung cancer
targeted therapy
target
drug resistance
